|Assessment Status||Rapid Review Complete|
|Drug||Autologous anti-CD19-transduced CD3+ cells|
|Indication||For the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor.|
|Rapid review commissioned||03/03/2021|
|Rapid review completed||22/03/2021|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of autologous anti-CD19-transduced CD3+ cells compared with the current standard of care|
|Full pharmacoeconomic assessment commissioned by HSE||31/03/2021|
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.